cardiology MCQ (SBA): ACC Expert Consensus Pathway (2022): Nonstatin Therapies for LDL-C Lowering

Instant feedback + full explanation. One question, done properly.

MediumPCSK9 inhibitorsACC Expert Consensus Pathway (2022): Nonstatin Therapies for LDL-C Loweringcardiology

A 60-year-old with dyslipidemia and ASCVD on maximally tolerated statin has LDL-C 76 mg/dL. What is next per ACC nonstatin pathway?

Practice more on iatroX

Educational content. Not a substitute for clinical judgement or local policy.

cardiology MCQ: ACC Expert Consensus Pathway (2022): Nonstatin Therapi